Yahoo
NasdaqCM - BOATS Real Time Price USD

IceCure Medical Ltd (ICCM)

5.96 -1.06 (-15.10%)
At close: June 26 at 4:00:01 PM EDT
6.00 +0.04 (+0.67%)
Overnight: 9:57:15 PM EDT
Chart Range Bar
Loading chart for ICCM
Chart does not reflect overnight price.
  • Previous Close 7.02
  • Open 6.51
  • Bid 9.10 x 100
  • Ask 9.10 x 1400
  • Day's Range 5.56 - 6.55
  • 52 Week Range 2.12 - 42.00
  • Volume 779,450
  • Avg. Volume 3,258,880
  • Market Cap (intraday) 20.421M
  • Beta (5Y Monthly) 1.49
  • PE Ratio (TTM) --
  • EPS (TTM) -7.20
  • Earnings Date (est.) Aug 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 30.50

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

www.icecure-medical.com

67

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 6/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICCM
67.43%
S&P 500 (^GSPC)
7.43%

1-Year Return

ICCM
80.43%
S&P 500 (^GSPC)
19.75%

3-Year Return

ICCM
82.72%
S&P 500 (^GSPC)
69.89%

5-Year Return

ICCM
98.33%
S&P 500 (^GSPC)
71.79%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 1.28M
Earnings --

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-3M
-2M
-1M
0
1M

Analyst Insights

View More

Analyst Price Targets

30.00
30.50 Average
5.96 Current
31.50 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/14/2026
Analyst Maxim Group
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 3 -> 1

Statistics

View More

Valuation Measures

Annual
As of 6/26/2026
  • Market Cap

    20.27M

  • Enterprise Value

    12.29M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.74

  • Price/Book (mrq)

    2.39

  • Enterprise Value/Revenue

    3.45

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -80.32%

  • Return on Equity (ttm)

    -217.23%

  • Revenue (ttm)

    3.56M

  • Net Income Avi to Common (ttm)

    -15.74M

  • Diluted EPS (ttm)

    -7.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.12M

  • Total Debt/Equity (mrq)

    1.64%

  • Levered Free Cash Flow (ttm)

    -8.88M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.96 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: